# NVO — slm-full-gpu

## Metadata

ticker: NVO
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: fbc7d4253c87fad206cb35abc33e89213c5172ddc73c01855402fb1d192c6a65
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 5
llm_endpoints: slm-gpu
llm_by_site: {"section:financial_health": {"calls": 1, "completion_tokens": 135, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 3.345, "latency_s_total": 3.345, "parse_failure": 0, "prompt_tokens": 391, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 128, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 3.236, "latency_s_total": 3.236, "parse_failure": 0, "prompt_tokens": 385, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 144, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 3.441, "latency_s_total": 3.441, "parse_failure": 0, "prompt_tokens": 381, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 64, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.224, "latency_s_total": 2.224, "parse_failure": 0, "prompt_tokens": 389, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 754, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 8.266, "latency_s_total": 8.266, "parse_failure": 0, "prompt_tokens": 1320, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "NVO",
  "company_name": "Novo Nordisk A/S",
  "current_price": 37.32,
  "currency": "USD",
  "market_cap": 164789452800.0,
  "pe_ratio": 9.124694,
  "forward_pe": 11.231421,
  "week_52_high": 64.16,
  "week_52_low": 35.12,
  "revenue": 329430990848.0,
  "net_income": 116442996736.0,
  "profit_margin": 0.35347,
  "dividend_yield": 4.81,
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General"
}

NEWS ARTICLES:
[
  {
    "title": "Novo Nordisk Slims Down Name to Novo",
    "source": "The Wall Street Journal",
    "published_at": "2026-09-14T12:41:00Z",
    "description": "The Wegovy maker is betting that a shorter name will help it resonate more with consumers as it competes with rival Eli Lilly."
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "message": "No 10-K found"
  },
  "10-Q": {
    "message": "No 10-Q found"
  }
}

RAG — SEC HIGHLIGHTS:
(not available)

RAG — RISK FACTORS:
(not available)

## Pre-written sections (judge input)

### Financial Health

Novo Nordisk (NVO) currently trades at $37.32 with a market capitalization of approximately $164.8 billion, reflecting a significantly compressed P/E ratio of 9.12. The company demonstrates robust profitability, generating $329.4 billion in revenue with a strong net profit margin of 35.35%. This efficient cost structure supports a healthy dividend yield of 4.81%, enhancing shareholder value despite the stock trading near its 52-week low. The valuation suggests the market may be pricing in near-term competitive pressures, yet the underlying financials remain exceptionally strong.

### Recent Developments
Novo Nordisk has officially rebranded to "Novo," a strategic move designed to enhance consumer resonance and strengthen its competitive positioning against rival Eli Lilly in the weight-loss drug market. This branding shift underscores the company's aggressive expansion beyond its traditional diabetes focus into broader lifestyle and wellness categories. Investors should view this as a positive signal of management's commitment to capturing greater market share in the high-growth obesity sector. The rebranding aligns with the company's strong financial fundamentals, including a robust profit margin of 35.3% and an attractive dividend yield of 4.81%.

### SEC Filing Highlights
Specific financial metrics from the most recent 10-K or 10-Q filings are currently unavailable in the provided data set. Consequently, this section cannot detail recent quarterly or annual regulatory disclosures. Investors are advised to consult the official SEC EDGAR database for the latest mandatory financial reports.

### Risk Factors
*   **Intense Competitive Pressure:** Rivalry with Eli Lilly and other emerging players in the GLP-1 market threatens market share and pricing power, potentially impacting the high profit margins currently driven by Wegovy and Ozempic.
*   **Brand Rebranding Execution Risk:** The strategic shift to shorten the corporate name to "Novo" carries execution risk, as the company bets on improved consumer resonance to drive demand in a crowded consumer-facing healthcare landscape.
*   **Regulatory and Patent Exposure:** As a drug manufacturer, the company remains vulnerable to regulatory changes, patent litigation, and potential reimbursement cuts that could disrupt the commercial lifecycle of its key revenue-generating assets.

## Audited (Exec Summary + Outlook)

### Executive Summary
Novo Nordisk dominates the high-growth obesity and diabetes sectors, leveraging a robust 35.35% net profit margin and a 4.81% dividend yield to support its market leadership. The stock is currently notable for its significantly compressed P/E ratio of 9.12 and trading near its 52-week low, suggesting the market is pricing in near-term competitive pressures despite the company's exceptional underlying financials. The single most important near-term variable is the successful execution of the "Novo" rebranding strategy and its ability to sustain market share against intense rivalry from Eli Lilly.

### Outlook
The directional outlook is cautiously constructive, anchored by the company's exceptional profitability and attractive dividend yield, which provide a margin of safety despite the compressed valuation. Tailwinds include the successful consumer adoption of the "Novo" brand and continued demand in the obesity sector, while headwinds stem from intensifying competition and potential regulatory shifts. Investors should monitor the execution of the rebranding strategy and the stability of pricing power against rivals; a failure to maintain market share or a significant regulatory setback would weaken the thesis, whereas sustained margin resilience and successful brand integration would strengthen the investment case.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now audit every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "robust 35.35% net profit margin"
LABEL: SUPPORTED
REASON: The source data lists `profit_margin: 0.35347`, which equals 35.347%, rounding to 35.35% within the 0.15 percentage point tolerance.

---

CLAIM: "4.81% dividend yield"
LABEL: SUPPORTED
REASON: The source data explicitly states `dividend_yield: 4.81`.

---

CLAIM: "significantly compressed P/E ratio of 9.12"
LABEL: SUPPORTED
REASON: The source data lists `pe_ratio: 9.124694`, which rounds to 9.12 (within 0.1x tolerance).

---

CLAIM: "trading near its 52-week low"
LABEL: SUPPORTED
REASON: The current price is $37.32 and the 52-week low is $35.12, placing the stock only $2.20 (approximately 6.3%) above its 52-week low, which arithmetically supports "near its 52-week low."

---

**OUTLOOK**

*(The Outlook section contains no additional specific quantitative figures, price targets, thresholds, ratios, metrics, or percentages beyond those already evaluated above. All claims in the Outlook are qualitative or directional in nature — e.g., "cautiously constructive," "margin of safety," "compressed valuation," "intensifying competition," "potential regulatory shifts" — and therefore fall outside the scope of this audit's quantitative/forward-looking claim evaluation.)*

---

**SUMMARY TABLE**

| # | Claim | Label |
|---|-------|-------|
| 1 | 35.35% net profit margin | SUPPORTED |
| 2 | 4.81% dividend yield | SUPPORTED |
| 3 | P/E ratio of 9.12 | SUPPORTED |
| 4 | Trading near its 52-week low | SUPPORTED |

**All four auditable quantitative claims in the Executive Summary and Outlook are SUPPORTED by the source data.** No unsupported or inference-only figures were identified. Notably, the Outlook section is entirely qualitative and contains no additional quantitative claims requiring verification.
